02 Dec 2015 Posted in ABPI statement By Press Office
"Diabetes experts had expressed concerns about the previous guidelines due to their focus on cost over clinical care. Nice has addressed these concerns and today’s announcement should encourage clinicians to adopt an individualised approach to treatment, tailored to meet the needs of each patient. This will result in greater long-term health benefits for patients. We are pleased to have had the opportunity to work with NICE and to contribute to this important guidance.
"We believe these guidelines now represent ‘one voice’ from the diabetes community - doctors, patient groups, science leaders and the pharmaceutical industry - and this can only be positive.
"New medicines will continue to play a vital role in the management of patients with type 2 diabetes over the coming years. The pharmaceutical industry has committed to providing hundreds of millions of pounds to the NHS in order to help fund new, innovative medicines. We hope this provides clinicians with more flexibility to prescribe the medicines best suited to meet the needs of their individual patients.”